RayKnowChina Research Map
Shortlist

Cancer

Lung cancer

肺癌

Tumours or cancer of the lung.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
251

with a paper from 2016–2025 or a registered study

cities
73

where those hospitals are

open trials in China
1,008

ClinicalTrials.gov, 18 Nov 2026

Mainland China accounts for 40% of the world's English-language research papers on lung cancer, 2021–2025 (28% in 2016–2020), and 25% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

251 hospitals in 73 cities

Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 25 papers or 1 trial on lung cancer, or was a site in 16 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Shanghai22
  2. Beijing20
  3. Guangzhou17
  4. Hangzhou11
  5. Chongqing9
  6. Jinan9
  7. Nanjing8
  8. Tianjin7
  9. Changsha6
  10. Hefei6

Each opens lung cancer in that city. 63 more cities are in the menu below.

  1. 682 papers led
  2. 587 papers led
  3. Shanghai Chest Hospital

    上海市胸科医院Shanghai

    414 papers led
  4. 394 papers led
  5. 357 papers led
  6. 328 papers led
  7. 258 papers led
  8. 243 papers led
  9. 236 papers led
  10. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    233 papers led
  11. 213 papers led
  12. 204 papers led
  13. 204 papers led
  14. 186 papers led
  15. 186 papers led
  16. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    186 papers led
  17. Xiangya Hospital

    中南大学湘雅医院Changsha

    183 papers led
  18. 181 papers led
    No open trial led
  19. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    176 papers led
    No open trial led
  20. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    176 papers led
  21. 161 papers led
    No open trial led
  22. 161 papers led
  23. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    156 papers led
    No open trial led
  24. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    151 papers led
  25. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    147 papers led
  26. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    140 papers led
  27. 137 papers led
  28. 135 papers led
    No open trial led
  29. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    127 papers led
  30. 125 papers led
  31. 124 papers led
    No open trial led
  32. 123 papers led
  33. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    123 papers led
  34. 122 papers led
    No open trial led
  35. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    120 papers led
  36. 115 papers led
  37. 112 papers led
  38. 111 papers led
    No open trial led
  39. Sichuan Cancer Hospital

    四川省肿瘤医院Chengdu

    111 papers led
  40. 105 papers led
  41. 105 papers led
  42. 104 papers led
    No open trial led
  43. 103 papers led
    No open trial led
  44. 102 papers led
    No open trial led
  45. 102 papers led
  46. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    99 papers led
  47. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    92 papers led
  48. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    89 papers led
  49. 88 papers led
  50. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    88 papers led
  51. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    83 papers led
  52. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    83 papers led
  53. 82 papers led
    No open trial led
  54. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    82 papers led
  55. 81 papers led
  56. Beijing Chest Hospital

    首都医科大学附属北京胸科医院Beijing

    80 papers led
  57. Yunnan Cancer Hospital

    云南省肿瘤医院Kunming

    78 papers led
  58. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    77 papers led
  59. Fujian Cancer Hospital

    福建省肿瘤医院Fuzhou

    77 papers led
  60. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    76 papers led
    No open trial led
  61. 75 papers led
    No open trial led
  62. 74 papers led
    No open trial led
  63. 74 papers led
    No open trial led
  64. 71 papers led
    No open trial led
  65. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    69 papers led
  66. 69 papers led
  67. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    69 papers led
  68. 68 papers led
  69. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    68 papers led
  70. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    68 papers led
  71. 67 papers led
  72. 66 papers led
  73. 66 papers led
    No open trial led
  74. 65 papers led
  75. 64 papers led
  76. 62 papers led
    No open trial led
  77. Second Hospital of Dalian Medical University

    大连医科大学附属第二医院Dalian

    62 papers led
  78. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    61 papers led
    No open trial led
  79. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    61 papers led
  80. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    60 papers led
    No open trial led
  81. 60 papers led
  82. Central Hospital Affiliated to Shandong First Medical University

    山东第一医科大学附属中心医院(济南市中心医院)Jinan

    59 papers led
    No open trial led
  83. 59 papers led
    No open trial led
  84. 59 papers led
    No open trial led
  85. 58 papers led
    No open trial led
  86. 57 papers led
  87. 56 papers led
  88. Ningbo Medical Center Lihuili Hospital

    宁波市医疗中心李惠利医院Ningbo

    55 papers led
    No open trial led
  89. 55 papers led
  90. 54 papers led
    No open trial led
  91. 53 papers led
  92. 53 papers led
    No open trial led
  93. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    51 papers led
    No open trial led
  94. 51 papers led
    No open trial led
  95. 51 papers led
    No open trial led
  96. 51 papers led
  97. First Affiliated Hospital of Zhejiang Chinese Medical University

    浙江中医药大学附属第一医院(浙江省中医院)Hangzhou

    50 papers led
    No open trial led
  98. 50 papers led
  99. Shanghai General Hospital

    上海市第一人民医院Shanghai

    49 papers led
  100. 48 papers led
    No open trial led
  101. 47 papers led
    No open trial led
  102. 47 papers led
  103. 47 papers led
  104. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    47 papers led
    No open trial led
  105. Cancer Hospital CAMS – Shenzhen

    中国医学科学院肿瘤医院深圳医院Shenzhen

    46 papers led
    No open trial led
  106. 45 papers led
    No open trial led
  107. 45 papers led
  108. 45 papers led
    No open trial led
  109. Longhua Hospital

    上海中医药大学附属龙华医院Shanghai

    44 papers led
    No open trial led
  110. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    43 papers led
    No open trial led
  111. 43 papers led
    No open trial led
  112. Huadong Hospital, Fudan University

    复旦大学附属华东医院Shanghai

    42 papers led
    No open trial led
  113. 42 papers led
    No open trial led
  114. 41 papers led
    No open trial led
  115. 41 papers led
    No open trial led
  116. Hubei Cancer Hospital

    湖北省肿瘤医院Wuhan

    41 papers led
  117. 41 papers led
    No open trial led
  118. 41 papers led
    No open trial led
  119. Xuzhou Central Hospital

    徐州市中心医院Xuzhou

    41 papers led
    No open trial led
  120. 40 papers led
    No open trial led
  121. Changzheng Hospital

    海军军医大学第二附属医院(长征医院)Shanghai

    40 papers led
    No open trial led
  122. Guangxi Medical University Cancer Hospital

    广西医科大学附属肿瘤医院Nanning

    39 papers led
    No open trial led
  123. Jilin Cancer Hospital

    吉林省肿瘤医院Changchun

    39 papers led
    No open trial led
  124. Tianjin Chest Hospital

    天津市胸科医院Tianjin

    39 papers led
    No open trial led
  125. 38 papers led
    No open trial led
  126. 38 papers led
    No open trial led
  127. 37 papers led
    No open trial led
  128. 37 papers led
    No open trial led
  129. 37 papers led
    No open trial led
  130. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    36 papers led
  131. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    36 papers led
  132. 35 papers led
    No open trial led
  133. 34 papers led
    No open trial led
  134. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    34 papers led
    No open trial led
  135. 34 papers led
    No open trial led
  136. Taizhou Hospital, Wenzhou Medical University

    温州医科大学附属台州医院Taizhou

    34 papers led
    No open trial led
  137. 33 papers led
    No open trial led
  138. 33 papers led
    No open trial led
  139. 33 papers led
  140. Shanghai Ninth People's Hospital

    上海交通大学医学院附属第九人民医院Shanghai

    33 papers led
    No open trial led
  141. 32 papers led
    No open trial led
  142. 32 papers led
    No open trial led
  143. Guang'anmen Hospital

    中国中医科学院广安门医院Beijing

    32 papers led
  144. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    32 papers led
    No open trial led
  145. Xijing Hospital

    空军军医大学西京医院Xi'an

    32 papers led
  146. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    32 papers led
    No open trial led
  147. 31 papers led
  148. 31 papers led
    No open trial led
  149. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    31 papers led
    No open trial led
  150. Taihe Hospital

    十堰市太和医院Shiyan

    31 papers led
    No open trial led
  151. 31 papers led
    No open trial led
  152. 30 papers led
    No open trial led
  153. 30 papers led
    No open trial led
  154. 30 papers led
    No open trial led
  155. 30 papers led
    No open trial led
  156. 30 papers led
    No open trial led
  157. 30 papers led
    No open trial led
  158. Tongji Hospital

    同济大学附属同济医院Shanghai

    30 papers led
    No open trial led
  159. 30 papers led
    No open trial led
  160. Hunan Provincial People's Hospital

    湖南省人民医院(湖南师范大学附属第一医院)Changsha

    29 papers led
    No open trial led
  161. 29 papers led
    No open trial led
  162. 28 papers led
    No open trial led
  163. 28 papers led
    No open trial led
  164. 28 papers led
  165. 28 papers led
    No open trial led
  166. 28 papers led
    No open trial led
  167. 28 papers led
  168. 27 papers led
    No open trial led
  169. 26 papers led
  170. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    26 papers led
  171. 25 papers led
    No open trial led
  172. 25 papers led
    No open trial led
  173. 25 papers led
    No open trial led
  174. 23 papers led
    No open trial led
  175. 23 papers led
    No open trial led
  176. 23 papers led
    No open trial led
  177. 22 papers led
    No open trial led
  178. Jiangxi Cancer Hospital

    江西省肿瘤医院Nanchang

    22 papers led
    No open trial led
  179. Shanxi Cancer Hospital

    山西省肿瘤医院Taiyuan

    21 papers led
  180. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    20 papers led
  181. 20 papers led
    No open trial led
  182. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    19 papers led
    No open trial led
  183. 19 papers led
  184. 19 papers led
    No open trial led
  185. Tianjin First Central Hospital

    天津市第一中心医院Tianjin

    19 papers led
  186. Yichang Central People's Hospital

    宜昌市中心人民医院Yichang

    19 papers led
  187. Beijing Tiantan Hospital

    首都医科大学附属北京天坛医院BeijingInternational Department

    18 papers led
    No open trial led
  188. 18 papers led
  189. 18 papers led
    No open trial led
  190. 17 papers led
    No open trial led
  191. 17 papers led
  192. Anhui Chest Hospital

    安徽省胸科医院Hefei

    16 papers led
    No open trial led
  193. 16 papers led
    No open trial led
  194. 15 papers led
  195. 15 papers led
    No open trial led
  196. 14 papers led
    No open trial led
  197. 13 papers led
  198. 13 papers led
  199. 11 papers led
    No open trial led
  200. 10 papers led
  201. 9 papers led
    No open trial led
  202. 9 papers led
    No open trial led
  203. Fourth Affiliated Hospital of Zhejiang University

    浙江大学医学院附属第四医院Hangzhou

    9 papers led
  204. Linyi People's Hospital

    临沂市人民医院Linyi

    9 papers led
    No open trial led
  205. 9 papers led
  206. 8 papers led
    No open trial led
  207. 8 papers led
    No open trial led
  208. First People's Hospital of Foshan

    佛山市第一人民医院Foshan

    7 papers led
    No open trial led
  209. Anyang Tumor Hospital

    安阳市肿瘤医院Anyang

    6 papers led
    No open trial led
  210. 6 papers led
    No open trial led
  211. Shanghai Proton and Heavy Ion Center

    上海市质子重离子医院Shanghai

    6 papers led
  212. Shanxi Bethune Hospital

    山西白求恩医院Taiyuan

    6 papers led
    No open trial led
  213. 5 papers led
    No open trial led
  214. Quanzhou First Hospital, Fujian Medical University

    福建医科大学附属泉州第一医院Quanzhou

    5 papers led
  215. Taizhou Hospital

    浙江省台州医院Taizhou

    5 papers led
    No open trial led
  216. Yishui Central Hospital

    临沂市中心医院Linyi

    4 papers led
    No open trial led
  217. Linyi Cancer Hospital

    临沂市肿瘤医院Linyi

    3 papers led
    No open trial led
  218. Nantong Tumor Hospital

    南通市肿瘤医院Nantong

    3 papers led
    No open trial led
  219. 2 papers led
  220. Qingdao Central Hospital

    康复大学青岛中心医院Qingdao

    2 papers led
  221. 2 papers led
  222. Third Affiliated Hospital of Harbin Medical University

    哈尔滨医科大学第三临床医学院Harbin

    2 papers led
  223. 2 papers led
  224. 1 paper led
  225. 1 paper led
  226. 1 paper led
  227. 1 paper led
    No open trial led
  228. 1 paper led
    No open trial led
  229. 1 paper led
    No open trial led
  230. 1 paper led
    No open trial led
  231. 0 papers led
    No open trial led
  232. 0 papers led
    No open trial led
  233. 0 papers led
  234. 0 papers led
  235. 0 papers led
  236. Beijing Haidian Hospital

    北京市海淀医院Beijing

    0 papers led
  237. 0 papers led
    No open trial led
  238. 0 papers led
    No open trial led
  239. 0 papers led
  240. 0 papers led
  241. Fuda Cancer Hospital

    广州复大肿瘤医院Guangzhou

    0 papers led
    No open trial led
  242. 0 papers led
    No open trial led
  243. 0 papers led
    No open trial led
  244. 0 papers led
    No open trial led
  245. 0 papers led
    No open trial led
  246. 0 papers led
    No open trial led
  247. 0 papers led
    No open trial led
  248. PLA Navy Anqing Hospital

    中国人民解放军海军安庆医院Anqing

    0 papers led
    No open trial led
  249. 0 papers led
    No open trial led
  250. 0 papers led
  251. Xuzhou Second People's Hospital

    徐州市第二人民医院Xuzhou

    0 papers led
    No open trial led

By university or health system 59

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    945 papers led
    6 hospitals
  2. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    773 papers led
    6 hospitals
  3. Sichuan University (West China)

    四川大学华西Chengdu

    731 papers led
    6 hospitals
  4. Nanjing Medical University

    南京医科大学Nanjing

    653 papers led
    6 hospitals
  5. Fudan University

    复旦大学Shanghai

    637 papers led
    6 hospitals
  6. Shandong First Medical University

    山东第一医科大学Jinan

    636 papers led
    6 hospitals
  7. Sun Yat-sen University

    中山大学Guangzhou

    573 papers led
    6 hospitals
  8. Tongji University

    同济大学Shanghai

    558 papers led
    6 hospitals
  9. Central South University (Xiangya)

    中南大学湘雅Changsha

    500 papers led
    6 hospitals
  10. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    476 papers led
    6 hospitals
  11. Zhengzhou University

    郑州大学Zhengzhou

    464 papers led
    6 hospitals
  12. Peking University Health Science Center

    北京大学医学部Beijing

    458 papers led
    6 hospitals
  13. Tianjin Medical University

    天津医科大学Tianjin

    416 papers led
    6 hospitals
  14. Soochow University

    苏州大学Suzhou

    375 papers led
    6 hospitals
  15. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    374 papers led
    6 hospitals
  16. China Medical University (Shenyang)

    中国医科大学Shenyang

    370 papers led
    6 hospitals
  17. Capital Medical University

    首都医科大学Beijing

    369 papers led
    6 hospitals
  18. Fujian Medical University

    福建医科大学Fuzhou

    345 papers led
    6 hospitals
  19. Guangzhou Medical University

    广州医科大学Guangzhou

    307 papers led
    6 hospitals
  20. Shandong University

    山东大学Jinan

    306 papers led
    6 hospitals
  21. Wenzhou Medical University

    温州医科大学Wenzhou

    302 papers led
    6 hospitals
  22. Harbin Medical University

    哈尔滨医科大学Harbin

    299 papers led
    6 hospitals
  23. Chongqing Medical University

    重庆医科大学Chongqing

    264 papers led
    6 hospitals
  24. Xi'an Jiaotong University

    西安交通大学Xi'an

    258 papers led
    6 hospitals
  25. Nanchang University

    南昌大学Nanchang

    243 papers led
    6 hospitals
  26. Qingdao University

    青岛大学Qingdao

    231 papers led
    6 hospitals
  27. Hebei Medical University

    河北医科大学Shijiazhuang

    224 papers led
    6 hospitals
  28. Southern Medical University

    南方医科大学Guangzhou

    212 papers led
    6 hospitals
  29. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    207 papers led
    2 hospitals
  30. Jilin University

    吉林大学Changchun

    206 papers led
    3 hospitals
  31. Wuhan University

    武汉大学Wuhan

    192 papers led
    3 hospitals
  32. Nantong University

    南通大学Nantong

    181 papers led
    1 hospital
  33. Guangxi Medical University

    广西医科大学Nanning

    180 papers led
    6 hospitals
  34. 177 papers led
    3 hospitals
  35. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    176 papers led
    1 hospital
  36. Nanjing University

    南京大学Nanjing

    176 papers led
    6 hospitals
  37. Army Medical University

    陆军军医大学Chongqing

    175 papers led
    5 hospitals
  38. Kunming Medical University

    昆明医科大学Kunming

    171 papers led
    6 hospitals
  39. Anhui Medical University

    安徽医科大学Hefei

    166 papers led
    6 hospitals
  40. Air Force Medical University

    空军军医大学Xi'an

    140 papers led
    6 hospitals
  41. 132 papers led
    6 hospitals
  42. Xuzhou Medical University

    徐州医科大学Xuzhou

    130 papers led
    6 hospitals
  43. Chongqing University

    重庆大学Chongqing

    129 papers led
    6 hospitals
  44. Southwest Medical University

    西南医科大学Luzhou

    122 papers led
    1 hospital
  45. 112 papers led
    2 hospitals
  46. Jinan University

    暨南大学Guangzhou

    104 papers led
    6 hospitals
  47. Bengbu Medical University

    蚌埠医科大学Bengbu

    102 papers led
    1 hospital
  48. Naval Medical University

    海军军医大学Shanghai

    92 papers led
    6 hospitals
  49. Xiamen University

    厦门大学Xiamen

    75 papers led
    6 hospitals
  50. Guangdong Medical University

    广东医科大学Zhanjiang

    67 papers led
    5 hospitals
  51. Xinjiang Medical University

    新疆医科大学Urumqi

    63 papers led
    6 hospitals
  52. Jiangnan University

    江南大学Wuxi

    59 papers led
    4 hospitals
  53. Shenzhen University

    深圳大学Shenzhen

    56 papers led
    6 hospitals
  54. Shantou University Medical College

    汕头大学医学院Shantou

    55 papers led
    1 hospital
  55. Guizhou Medical University

    贵州医科大学Guiyang

    51 papers led
    3 hospitals
  56. Chengdu University

    成都大学Chengdu

    44 papers led
    2 hospitals
  57. Ningxia Medical University

    宁夏医科大学Yinchuan

    43 papers led
    2 hospitals
  58. Guilin Medical University

    桂林医学院Guilin

    37 papers led
    1 hospital
  59. Guangdong Pharmaceutical University

    广东药科大学Guangzhou

    21 papers led
    2 hospitals

1,008

open trials on lung cancer in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 636 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT06951646

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 12 listed hospitals as study sitesChangsha, Chongqing, Nanchang, Nanning, Shenyang, Taiyuan, Wuhan, Xinxiang

  2. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  3. Recruiting
    Durvalumab as Consolidation for Patients LS-SCLC
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07055581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou

  4. Recruiting
    A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
    Phase
    Phase 2/Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07063745

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen

  5. Recruiting
    Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07076836

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  6. Recruiting
    A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07103395

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  7. Recruiting
    HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT07105176

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  8. Recruiting
    A Study of DXC014 in Patients With Advanced Solid Tumors.
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07177937

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Qingdao

  9. Recruiting
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07195695

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou

  10. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  11. Recruiting
    A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07227025

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Harbin, Shanghai

  12. Recruiting
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07227298

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan

  13. Recruiting
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07227597

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou

  14. Recruiting
    A Phase II Study of SKB571 in Patients With Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07230405

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhengzhou

  15. Recruiting
    Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07231445

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  16. Recruiting
    TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07246304

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  17. Recruiting
    This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07249879

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  18. Recruiting
    Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07251582

    Age 18 years to 75 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  19. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07253142

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuhan, Xinxiang, Xuzhou

  20. Recruiting
    A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07264816

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  21. Recruiting
    A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07269782

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  22. Recruiting
    Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07288177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Nanjing, Shanghai, Tianjin, Zhengzhou

  23. Recruiting
    SKB500 Combinations in Patients With Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07296809

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  24. Recruiting
    A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07308106

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  25. Recruiting
    A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07309276

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  26. Recruiting
    The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07310056

    Age 18 years to 85 years (registered criteria)

    Led by West China HospitalChengdu

  27. Recruiting
    Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07314216

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  28. Recruiting
    Acupressure for Cough in Lung Cancer Survivors
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07315672

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  29. Recruiting
    Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
    Phase
    Phase 4
    Started
    2026-01
    Posted
    Registry
    NCT07320105

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  30. Recruiting
    Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07323056

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  31. Recruiting
    A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07325136

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai East Hospital, Tongji UniversityShanghai

  32. Recruiting
    Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07329322

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  33. Recruiting
    First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07332858

    Age 18 years to 75 years (registered criteria)

    Led by China-Japan Friendship HospitalBeijing

  34. Recruiting
    Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07336732

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  35. Recruiting
    Electro-Acupuncture in Lung cancER : EALER Study
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07337096

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou

  36. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  37. Recruiting
    Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07348965

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  38. Recruiting
    Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07354061

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  39. Recruiting
    A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07354711

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  40. Recruiting
    A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07358676

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  41. Recruiting
    A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07361497

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou

  42. Recruiting
    A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07361510

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shantou

  43. Recruiting
    Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07361705

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Shenyang, Taiyuan, Zhengzhou

  44. Recruiting
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07367529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan

  45. Recruiting
    Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07374614

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Shenzhen HospitalShenzhen

  46. Recruiting
    YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
    Phase
    N/A
    Started
    2026-12
    Posted
    Registry
    NCT07390565

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  47. Recruiting
    Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07398599

    Age 18 years to 99 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  48. Recruiting
    Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07398937

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  49. Recruiting
    IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07408635

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  50. Recruiting
    Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07410975

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  51. Recruiting
    A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07412262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Wuhan

  52. Recruiting
    A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07413042

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  53. Recruiting
    PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07416058

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  54. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  55. Recruiting
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07416695

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  56. Recruiting
    MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07431827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan

  57. Recruiting
    A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07434518

    Age 18 years to 100 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  58. Recruiting
    Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07435038

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  59. Recruiting
    A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07444437

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Zhengzhou

  60. Recruiting
    An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07452003

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  61. Recruiting
    The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
    Phase
    Early phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07459283

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuxi

  62. Recruiting
    A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07459751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  63. Recruiting
    Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07467863

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  64. Recruiting
    Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07472478

    Age 18 years to 80 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  65. Recruiting
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07472517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou

  66. Recruiting
    Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07476287

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou

  67. Recruiting
    A Retrospective Real-World Study Based on RATIONALE-307
    Phase
    Not given
    Started
    2026-02
    Posted
    Registry
    NCT07478809

    Age not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  68. Recruiting
    Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07480213

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  69. Recruiting
    Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07481786

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChongqing, Guangzhou

  70. Recruiting
    Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07486817

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  71. Recruiting
    Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07487883

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  72. Recruiting
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07489066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  73. Recruiting
    Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07492342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou

  74. Recruiting
    A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07502300

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou

  75. Recruiting
    Large Language Models Assist in Tumor MDT
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07504367

    Age 25 years to 33 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  76. Recruiting
    Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07505173

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  77. Recruiting
    MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07509333

    Age 60 years to 90 years (registered criteria)

    Led by West China HospitalChengdu

  78. Recruiting
    Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07515027

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  79. Recruiting
    JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07518160

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  80. Recruiting
    Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07528066

    Age not stated (registered criteria)

    Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin

  81. Recruiting
    Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07528274

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  82. Recruiting
    A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07541170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin

  83. Recruiting
    RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07541521

    Age not stated (registered criteria)

    Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin

  84. Recruiting
    A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07548060

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  85. Recruiting
    Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07549061

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  86. Recruiting
    Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07552467

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  87. Recruiting
    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07554339

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen

  88. Recruiting
    Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07554846

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  89. Recruiting
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07557225

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  90. Recruiting
    A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07559786

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  91. Recruiting
    A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
    Phase
    Phase 1/Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07559929

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  92. Recruiting
    A Phase II Study of GC101 in NSCLC
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07560111

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  93. Recruiting
    Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07561567

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  94. Recruiting
    IMP3-saRNA Vaccine in Advanced NSCLC
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07561723

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  95. Recruiting
    A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07562581

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  96. Recruiting
    Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07564557

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  97. Recruiting
    Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07565532

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  98. Recruiting
    A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07566052

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanning, Suzhou, Taiyuan

  99. Recruiting
    Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07583550

    Age 18 years to 75 years (registered criteria)

    Led by Jiangmen Central HospitalJiangmen

  100. Recruiting
    A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07586202

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin

  101. Recruiting
    Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07589205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  102. Recruiting
    AMT-116 in Combination With AK112 in Patients With Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07590531

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou

  103. Recruiting
    Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07596121

    Age 65 years to Not stated (registered criteria)

    Led by Tangdu HospitalXi'an

  104. Recruiting
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07609121

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  105. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07610798

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  106. Recruiting
    Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07612722

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  107. Recruiting
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07622186

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou

  108. Recruiting
    Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07622706

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  109. Recruiting
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07623356

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  110. Recruiting
    Association Between Screening Behaviors and Lung Cancer Spectrum
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07626177

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  111. Recruiting
    EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07637448

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  112. Recruiting
    A Study of HDM2020 in Patients With Advanced Sq-NSCLC
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07638891

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  113. Recruiting
    A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07640789

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  114. Recruiting
    Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07641023

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  115. Recruiting
    A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
    Phase
    Phase 2/Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07642024

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai

  116. Recruiting
    PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07645222

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  117. Recruiting
    A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07654400

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  118. Recruiting
    Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07655622

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  119. Recruiting
    SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07662395

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  120. Recruiting
    Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07668037

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  121. Recruiting
    A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07668752

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  122. Recruiting
    A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07672223

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai

  123. Recruiting
    Precision Navigation to Improve Community Cancer Screening Participation
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07676383

    Age 45 years to 74 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  124. Recruiting
    DLL3-Targeted PET/CT in Small Cell Lung Cancer
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07677787

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  125. Recruiting
    Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07681245

    Age 18 years to 90 years (registered criteria)

    Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  126. Recruiting
    Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
    Phase
    Early phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07689643

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  127. Recruiting
    Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07696832

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  128. Recruiting
    SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07697586

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  129. Recruiting
    DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
    Phase
    Phase 1/Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07707895

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesNanning, Shanghai

  130. Recruiting
    Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07709585

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  131. Recruiting
    A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
    Phase
    Phase 2/Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07739186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou

  132. Recruiting
    A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
    Phase
    Phase 2/Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07739199

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Wuhan

  133. Recruiting
    A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07739758

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shenyang

  134. Recruiting
    A Study of DS-3939a in Participants With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07739966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou

  135. Recruiting
    Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07744256

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  136. Recruiting
    Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07744529

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  137. Recruiting
    Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
    Phase
    Phase 4
    Started
    2026-07
    Posted
    Registry
    NCT07744698

    Age 18 years to 75 years (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  138. Recruiting
    Analgesic Effects of Retro-superior Costotransverse Ligament Space Block for Video-assisted Thoracoscopic Surgery
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07745881

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  139. Recruiting
    Effect of Modified Arm Positioning on Shoulder Pain After Thoracoscopic Lobectomy
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07746323

    Age 18 years to Not stated (registered criteria)

    Led by Child Health HospitalChengdu

  140. Recruiting
    ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07751536

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei

  141. Recruiting
    Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
    Phase
    Phase 4
    Started
    2026-06
    Posted
    Registry
    NCT07754812

    Age 70 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary Hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai

  142. Recruiting
    NK Cells Plus ICI for SCLC Maintenance
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07759856

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin First Central HospitalTianjin

  143. Recruiting
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07760012

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  144. Recruiting
    Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
    Phase
    N/A
    Started
    2026-07
    Posted
    Registry
    NCT07768124

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Yongchuan Hospital of Chongqing Medical UniversityChongqing

  145. Recruiting
    Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07778316

    Age 18 years to 99 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  146. Recruiting
    Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07783971

    Age 30 years to 80 years (registered criteria)

    Led by Army Hospital

  147. Recruiting
    A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07798947

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  148. Recruiting
    A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07802821

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  149. Recruiting
    Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07806604

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  150. Recruiting
    Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07807696

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  151. Recruiting
    Wireless Wearable Home Prehabilitation for Older Adults With NSCLC
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07809763

    Age 65 years to 85 years (registered criteria)

    Led by West China HospitalChengdu

  152. Recruiting
    SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07823855

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  153. Recruiting
    A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07824882

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  154. Recruiting
    A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
    Phase
    Phase 1
    Started
    2026-09
    Posted
    Registry
    NCT07830342

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  155. Recruiting
    CAIX-targeted PET/CT in Solid Tumors
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07833085

    Age 18 years to Not stated (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  156. Recruiting
    A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07843940

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Harbin, Shanghai

  157. Recruiting
    Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07848243

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  158. Recruiting
    Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07855965

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 3 listed hospitals as study sitesChengdu, Luzhou, Nanchong

  159. Recruiting
    An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07863167

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  160. Recruiting
    Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07863999

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary Hospital; 4 listed hospitals as study sitesShanghai

  161. Recruiting
    Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07874581

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  162. Recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  163. Recruiting
    Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07880353

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  164. Recruiting
    Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07886047

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha

  165. Recruiting
    Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07886229

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha

  166. Recruiting
    MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07894458

    Age 18 years to 85 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  167. Recruiting
    Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07905937

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang

  168. Recruiting
    ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07912190

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  169. Recruiting
    68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07914764

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  170. Recruiting
    Pragmatic AI-Assisted Lung Cancer Translational Study
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07941128

    Age 18 years to Not stated (registered criteria)

    Led by Sir Run Run Shaw Hospital; 1 listed hospital as study siteHangzhou, Zhengzhou

  171. Recruiting
    Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT05321316

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  172. Recruiting
    The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT05798845

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  173. Recruiting
    A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
    Phase
    Phase 1
    Started
    2025-09
    Posted
    Registry
    NCT06232083

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  174. Recruiting
    Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06296745

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Huizhou Hospital of Guangzhou Medical UniversityHuizhou

  175. Recruiting
    Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06348797

    Age 18 years to 70 years (registered criteria)

    Led by West China HospitalChengdu

  176. Recruiting
    A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06568939

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Harbin, Linyi, Nanchang, Nanning, Urumqi, Wuhan, Xi'an, Zhengzhou

  177. Recruiting
    A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06674252

    Age 65 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  178. Recruiting
    Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06687408

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Shanghai

  179. Recruiting
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06712316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou

  180. Recruiting
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06712355

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  181. Recruiting
    The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06738160

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  182. Recruiting
    A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06754930

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  183. Recruiting
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06758401

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  184. Recruiting
    Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06758700

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  185. Recruiting
    Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06768307

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  186. Recruiting
    A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06769295

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  187. Recruiting
    Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06769971

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  188. Recruiting
    Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06771960

    Age 18 years to 80 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  189. Recruiting
    Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06772623

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Nanchang, Nanjing, Shanghai, Taiyuan, Wuhan, Xi'an, Zhengzhou

  190. Recruiting
    Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06773507

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  191. Recruiting
    ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06775743

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  192. Recruiting
    Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06776588

    Age 18 years to 75 years (registered criteria)

    Led by Beidahuang Industry Group General Hospital

  193. Recruiting
    Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06780098

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou

  194. Recruiting
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06780137

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai

  195. Recruiting
    A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06792552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang

  196. Recruiting
    A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06793215

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan

  197. Recruiting
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06801834

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  198. Recruiting
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06809764

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou

  199. Recruiting
    Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06818149

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  200. Recruiting
    A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06829459

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  201. Recruiting
    Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06838208

    Age 18 years to Not stated (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  202. Recruiting
    A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06839105

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan

  203. Recruiting
    Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06840704

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha

  204. Recruiting
    DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06846762

    Age not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  205. Recruiting
    A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06848699

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Chongqing, Jinan

  206. Recruiting
    Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06849167

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  207. Recruiting
    Second-line Immunotherapy for ES-SCLC
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06853678

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  208. Recruiting
    A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06855771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Linyi, Nanchang, Nanning, Taizhou, Xiamen

  209. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06858813

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  210. Recruiting
    The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06861543

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  211. Recruiting
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06862869

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi

  212. Recruiting
    Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06864624

    Age 18 years to Not stated (registered criteria)

    Led by Tangdu Hospital; 2 listed hospitals as study sitesChangsha, Xi'an, Yinchuan

  213. Recruiting
    A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT06868485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Shanghai, Tianjin, Wuhan

  214. Recruiting
    Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06868732

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  215. Recruiting
    Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06869239

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  216. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  217. Recruiting
    Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06877299

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  218. Recruiting
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06890598

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an

  219. Recruiting
    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06892548

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou

  220. Recruiting
    Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06895031

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  221. Recruiting
    Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT06896422

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  222. Recruiting
    Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06897046

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  223. Recruiting
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06899126

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  224. Recruiting
    A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06901817

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  225. Recruiting
    Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06902350

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changchun

  226. Recruiting
    Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06903117

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  227. Recruiting
    Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06903377

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  228. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06907615

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  229. Recruiting
    PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06914427

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  230. Recruiting
    Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC(ARMOR2501)
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06924398

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  231. Recruiting
    Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06926140

    Age 18 years to 75 years (registered criteria)

    Led by Guang'anmen Hospital; 1 listed hospital as study siteBeijing, Hefei

  232. Recruiting
    Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06926790

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  233. Recruiting
    Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06927986

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  234. Recruiting
    Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06928389

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  235. Recruiting
    Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06929936

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  236. Recruiting
    A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06930794

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  237. Recruiting
    Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06930807

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  238. Recruiting
    18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06937112

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  239. Recruiting
    Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06939127

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  240. Recruiting
    Sleep Disorders and Tumor Immune Microenvironment
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT06941948

    Age 18 years to 70 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  241. Recruiting
    An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06942143

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  242. Recruiting
    Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06943235

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  243. Recruiting
    AK129 Combination Therapy for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06943820

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  244. Recruiting
    A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT06946927

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  245. Recruiting
    A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06947694

    Age 18 years to 75 years (registered criteria)

    Led by Xinqiao Hospital, Army Medical UniversityChongqing

  246. Recruiting
    A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06951464

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  247. Recruiting
    Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06953843

    Age 18 years to 75 years (registered criteria)

    Led by Xinqiao Hospital, Army Medical UniversityChongqing

  248. Recruiting
    A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06954246

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  249. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06955988

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  250. Recruiting
    Organoid-guided Personalized Treatment of Pleural Effusion
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06959173

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  251. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  252. Recruiting
    Bovine Reinforcement in Stomach, Colorectal and Lung Operation
    Phase
    Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06968221

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  253. Recruiting
    Transbronchial MWA for Pulmonary Tumors
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT06969014

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  254. Recruiting
    A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06969612

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  255. Recruiting
    PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06977074

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  256. Recruiting
    Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06987734

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  257. Recruiting
    Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT06992739

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  258. Recruiting
    A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07003321

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  259. Recruiting
    Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT07003490

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  260. Recruiting
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07005102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan

  261. Recruiting
    Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07008287

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  262. Recruiting
    Omitting CTV for Primary Tumor in LS-SCLC
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07008716

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  263. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  264. Recruiting
    Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07014202

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  265. Recruiting
    A Study of SKB518 in Patients With Lung Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07019675

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou

  266. Recruiting
    Tubeless Anesthesia in Preventing Lung Complications in Patients Undergoing Surgery for Early-Stage Lung Cancer
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT07024433

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  267. Recruiting
    A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT07026669

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  268. Recruiting
    Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07034326

    Age 18 years to 80 years (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

  269. Recruiting
    A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07034391

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  270. Recruiting
    ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07038096

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  271. Recruiting
    Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07039656

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  272. Recruiting
    Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07052669

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteChongqing, Guangzhou

  273. Recruiting
    A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07056556

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  274. Recruiting
    Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT07057102

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  275. Recruiting
    A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07058519

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  276. Recruiting
    Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07058948

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteBeijing, Tianjin

  277. Recruiting
    Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07059923

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  278. Recruiting
    Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07061535

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesChangsha, Hangzhou, Jinan

  279. Recruiting
    Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07063329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou

  280. Recruiting
    Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07066813

    Age not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  281. Recruiting
    DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07070440

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  282. Recruiting
    Study of GV20-0251 in Participants With Solid Tumor Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07070518

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  283. Recruiting
    Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07071103

    Age 18 years to 80 years (registered criteria)

    Led by Shantou University Medical College hospitalsShantou

  284. Recruiting
    Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07079475

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin

  285. Recruiting
    A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07082179

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  286. Recruiting
    Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07086300

    Age 65 years to 100 years (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

  287. Recruiting
    Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07086456

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  288. Recruiting
    Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07087223

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 7 listed hospitals as study sitesBeijing, Dalian, Shijiazhuang, Tianjin

  289. Recruiting
    Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07089199

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  290. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07090499

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  291. Recruiting
    A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07091305

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  292. Recruiting
    SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07096882

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  293. Recruiting
    Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
    Phase
    Phase 2/Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07100080

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Taiyuan, Wuhan

  294. Recruiting
    A Study of GV20-0251 in Advanced or Refractory Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07106827

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  295. Recruiting
    Perioperative Immunotherapy for Resectable Limited-Stage SCLC
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT07109401

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  296. Recruiting
    ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07109531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  297. Recruiting
    Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07110103

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 1 listed hospital as study siteBeijing, Chongqing

  298. Recruiting
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07111520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou

  299. Recruiting
    Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT07117890

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  300. Recruiting
    Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07120282

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  301. Recruiting
    Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07120698

    Age 28 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  302. Recruiting
    IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07122687

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  303. Recruiting
    SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
    Phase
    Phase 2/Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT07131319

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  304. Recruiting
    Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07134660

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  305. Recruiting
    Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07135856

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  306. Recruiting
    The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07138755

    Age 18 years to 75 years (registered criteria)

    Led by Third Xiangya Hospital; 1 listed hospital as study siteChangsha

  307. Recruiting
    Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07141264

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  308. Recruiting
    A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07143045

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou

  309. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07144280

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  310. Recruiting
    Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07150663

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  311. Recruiting
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07154706

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou

  312. Recruiting
    A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07155174

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Nanchang, Shanghai, Wuhan, Zhengzhou

  313. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07155187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Urumqi

  314. Recruiting
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07164170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou

  315. Recruiting
    Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07166003

    Age 18 years to 79 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  316. Recruiting
    HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07169552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  317. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  318. Recruiting
    A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07171606

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  319. Recruiting
    A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07174908

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  320. Recruiting
    Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07175220

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  321. Recruiting
    A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07178795

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  322. Recruiting
    A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07181473

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai, Wuhan, Zhengzhou

  323. Recruiting
    Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07181499

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai

  324. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  325. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  326. Recruiting
    Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07189455

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  327. Recruiting
    A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07190248

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  328. Recruiting
    A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07193641

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  329. Recruiting
    To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07195084

    Age 18 years to Not stated (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  330. Recruiting
    IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07198841

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Foshan, Guangzhou, Nanchang, Nanning, Shijiazhuang

  331. Recruiting
    Study on the Mechanism of Acquired Resistance of Entrectinib
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT07199959

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  332. Recruiting
    A Study of YL202 in Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07202364

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  333. Recruiting
    A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07206498

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Shanghai, Tianjin

  334. Recruiting
    A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07208773

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  335. Recruiting
    Intraoperative Paravertebral Block and Postoperative Complications
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT07211529

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  336. Recruiting
    A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07217301

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou

  337. Recruiting
    A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07218146

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  338. Recruiting
    Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07226999

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  339. Recruiting
    A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07229599

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  340. Recruiting
    A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07229729

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  341. Recruiting
    A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07232420

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  342. Recruiting
    Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07232433

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  343. Recruiting
    A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07232849

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  344. Recruiting
    Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07239661

    Age 18 years to Not stated (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

  345. Recruiting
    A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07241767

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  346. Recruiting
    Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07243873

    Age 18 years to 85 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Zunyi

  347. Recruiting
    Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT07244016

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  348. Recruiting
    A Study of Ivonescimab in First-Line ES-SCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07245446

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai, Xi'an

  349. Recruiting
    A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-10
    Posted
    Registry
    NCT07250386

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  350. Recruiting
    KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07252739

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Nanchang, Nanjing, Shanghai

  351. Recruiting
    Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07257458

    Age 18 years to 85 years (registered criteria)

    Led by Beijing Haidian HospitalBeijing

  352. Recruiting
    Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07257471

    Age 18 years to 85 years (registered criteria)

    Led by Beijing Haidian HospitalBeijing

  353. Recruiting
    VSV-02 Compassionate Use in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07260591

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xinxiang Medical UniversityXinxiang

  354. Recruiting
    A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07274852

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  355. Recruiting
    To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07291921

    Age 18 years to 85 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  356. Recruiting
    Exploratory Trial of Navigational Bronchoscopy-Guided Cryoablation in Lung Cancer Treatment
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07301411

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  357. Recruiting
    Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07304739

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  358. Recruiting
    Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07309952

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  359. Recruiting
    Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07322783

    Age 18 years to 80 years (registered criteria)

    Led by Qingdao Central HospitalQingdao

  360. Recruiting
    TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07330037

    Age 17 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  361. Recruiting
    WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07330050

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  362. Recruiting
    QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07330596

    Age 18 years to 75 years (registered criteria)

    Led by Anhui Provincial Cancer Hospital

  363. Recruiting
    68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07331532

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  364. Recruiting
    Functional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical Study
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07339644

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Chongqing Medical UniversityChongqing

  365. Recruiting
    Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07359040

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  366. Recruiting
    A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07361237

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai East Hospital, Tongji UniversityShanghai

  367. Recruiting
    A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07362459

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  368. Recruiting
    A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07362940

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Jinan, Xiamen, Zhengzhou

  369. Recruiting
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07371663

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou

  370. Recruiting
    A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07373964

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  371. Recruiting
    A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07375316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Shantou, Shenzhen

  372. Recruiting
    A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07376707

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  373. Recruiting
    A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
    Phase
    Phase 1
    Started
    2025-10
    Posted
    Registry
    NCT07381829

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  374. Recruiting
    Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07388771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Wuhan

  375. Recruiting
    Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07425795

    Age 18 years to 75 years (registered criteria)

    Led by Chongqing University Cancer HospitalChongqing

  376. Recruiting
    Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07443397

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  377. Recruiting
    FAP-targeted PET/NIR in Lung Malignant Tumors
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07498933

    Age 18 years to 70 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  378. Recruiting
    68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07508852

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  379. Recruiting
    FL-261 Imaging for Cancer Diagnosis and Staging
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07510321

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  380. Recruiting
    Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07534033

    Age 18 years to 80 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  381. Recruiting
    Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07559097

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  382. Recruiting
    Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07586826

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  383. Recruiting
    Multimodal AI-Guided Recovery Management After Lung Cancer Surgery
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT07588737

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  384. Recruiting
    Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07610616

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  385. Recruiting
    The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07617246

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  386. Recruiting
    Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07626736

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  387. Recruiting
    Effectiveness of Perioperative Percutaneous Acupuncture on Postoperative Sleep Disturbances and Chronic Pain in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT07662733

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  388. Recruiting
    Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07742332

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  389. Recruiting
    Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07748325

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  390. Recruiting
    PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07775820

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shenzhen, Wenzhou

  391. Recruiting
    Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07801430

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  392. Recruiting
    A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07815223

    Age 18 years to 75 years (registered criteria)

    Led by Yantai Yuhuangding HospitalYantai

  393. Recruiting
    Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07820423

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  394. Recruiting
    Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07837739

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  395. Recruiting
    Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT07895277

    Age 35 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  396. Recruiting
    Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT07947043

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  397. Recruiting
    Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT05266846

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  398. Recruiting
    Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT05613452

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  399. Recruiting
    First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT05745350

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  400. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Luoyang, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  401. Recruiting
    Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT05979818

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya HospitalChangsha

  402. Recruiting
    Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06020430

    Age 18 years to 75 years (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  403. Recruiting
    Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06032052

    Age 65 years to Not stated (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  404. Recruiting
    Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
    Phase
    N/A
    Started
    2024-03
    Posted
    Registry
    NCT06037733

    Age 18 years to 75 years (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  405. Recruiting
    Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery
    Phase
    Not given
    Started
    2024-03
    Posted
    Registry
    NCT06109454

    Age 18 years to 75 years (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  406. Recruiting
    Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06121505

    Age 18 years to 75 years (registered criteria)

    Led by West China Hospital; 4 listed hospitals as study sitesChengdu, Chongqing, Nanchong, Wuhan

  407. Recruiting
    Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06127303

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 2 listed hospitals as study sitesShanghai

  408. Recruiting
    Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06128837

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  409. Recruiting
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06172478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  410. Recruiting
    A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06179069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou

  411. Recruiting
    Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure:Phase I/II
    Phase
    Phase 1/Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06195189

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  412. Recruiting
    GPC3/Mesothelin-CAR-γδT Cells Against Cancers
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06196294

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  413. Recruiting
    MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
    Phase
    Not given
    Started
    2024-02
    Posted
    Registry
    NCT06198868

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  414. Recruiting
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06203210

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou

  415. Recruiting
    A Study of HLX42 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2024-03
    Posted
    Registry
    NCT06210815

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  416. Recruiting
    Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients
    Phase
    N/A
    Started
    2024-01
    Posted
    Registry
    NCT06215326

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  417. Recruiting
    Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06217757

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  418. Recruiting
    WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
    Phase
    Phase 1/Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06243003

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  419. Recruiting
    The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
    Phase
    N/A
    Started
    2024-03
    Posted
    Registry
    NCT06244264

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  420. Recruiting
    Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06256237

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  421. Recruiting
    Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06258642

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  422. Recruiting
    Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06269211

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 1 listed hospital as study siteGuangzhou, Shanghai

  423. Recruiting
    Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06283719

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  424. Recruiting
    Serplulimab Combined With CCRT for LS-SCLC.
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06295926

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  425. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  426. Recruiting
    Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06304441

    Age 18 years to 75 years (registered criteria)

    Led by Third People's Hospital, Guangzhou Medical UniversityGuangzhou

  427. Recruiting
    A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06306456

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Hefei, Nanjing, Shanghai, Taizhou, Zhengzhou

  428. Recruiting
    Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06311981

    Age 75 years to Not stated (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  429. Recruiting
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
    Phase
    Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06312137

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou

  430. Recruiting
    Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06338683

    Age 18 years to 80 years (registered criteria)

    Led by Qinghai Red Cross HospitalXining

  431. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  432. Recruiting
    Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06348927

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  433. Recruiting
    To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06352008

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  434. Recruiting
    Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06355609

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  435. Recruiting
    Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06361589

    Age 18 years to Not stated (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  436. Recruiting
    Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06363734

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  437. Recruiting
    A Study of GC203 TIL in Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06375187

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  438. Recruiting
    Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06379087

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  439. Recruiting
    Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06383728

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  440. Recruiting
    ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06388031

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  441. Recruiting
    A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06403735

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHarbin, Kunming, Nanchang, Shanghai

  442. Recruiting
    JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06416410

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou

  443. Recruiting
    A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06417008

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin

  444. Recruiting
    A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06421298

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chest HospitalBeijing

  445. Recruiting
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06422143

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou

  446. Recruiting
    A Study of FZ-AD005 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06424665

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Hangzhou, Shanghai

  447. Recruiting
    A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06424899

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  448. Recruiting
    ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06426511

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  449. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  450. Recruiting
    PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06429696

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  451. Recruiting
    A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06430437

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  452. Recruiting
    Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06431685

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  453. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06437509

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  454. Recruiting
    Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
    Phase
    Phase 3
    Started
    2024-09
    Posted
    Registry
    NCT06437977

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  455. Recruiting
    Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06440057

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  456. Recruiting
    Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06440954

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  457. Recruiting
    Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06445881

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  458. Recruiting
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06452277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen

  459. Recruiting
    Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06458894

    Age 60 years to 99 years (registered criteria)

    Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou

  460. Recruiting
    A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
    Phase
    Phase 1
    Started
    2024-06
    Posted
    Registry
    NCT06461156

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  461. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  462. Recruiting
    A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06467500

    Age 18 years to 75 years (registered criteria)

    Led by Yichang Central People's HospitalYichang

  463. Recruiting
    Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06467617

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chest HospitalBeijing

  464. Recruiting
    Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
    Phase
    Phase 4
    Started
    2024-03
    Posted
    Registry
    NCT06467786

    Age 18 years to Not stated (registered criteria)

    Led by Tangdu HospitalXi'an

  465. Recruiting
    A Phase Ib Study of GC101 in NSCLC
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06473961

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  466. Recruiting
    Adebrelimab + Apatinib in SCLC Maintenance Therapy
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06475209

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  467. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06475300

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  468. Recruiting
    Interventional Software for Multi-immunotherapy of Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06478108

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  469. Recruiting
    Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06480864

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  470. Recruiting
    A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06483282

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  471. Recruiting
    Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
    Phase
    N/A
    Started
    2024-03
    Posted
    Registry
    NCT06483295

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  472. Recruiting
    Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06483347

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  473. Recruiting
    TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06484816

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  474. Recruiting
    Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06485544

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  475. Recruiting
    Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06492421

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  476. Recruiting
    Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
    Phase
    Phase 3
    Started
    2024-09
    Posted
    Registry
    NCT06496048

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  477. Recruiting
    A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06496490

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi

  478. Recruiting
    Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06497530

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  479. Recruiting
    Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach(Radiogenomics-Lung)
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06500312

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  480. Recruiting
    Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06501391

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  481. Recruiting
    Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
    Phase
    N/A
    Started
    2024-01
    Posted
    Registry
    NCT06503744

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  482. Recruiting
    A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06505824

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  483. Recruiting
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06512051

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  484. Recruiting
    Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06514027

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  485. Recruiting
    Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06514118

    Age 18 years to 80 years (registered criteria)

    Led by Qingdao Central HospitalQingdao

  486. Recruiting
    Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06517953

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  487. Recruiting
    Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
    Phase
    Not given
    Started
    2024-06
    Posted
    Registry
    NCT06518655

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan

  488. Recruiting
    Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-09
    Posted
    Registry
    NCT06523673

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  489. Recruiting
    Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06527898

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  490. Recruiting
    Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
    Phase
    Not given
    Started
    2024-06
    Posted
    Registry
    NCT06528418

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  491. Recruiting
    Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06528847

    Age 18 years to 74 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  492. Recruiting
    Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06532591

    Age 18 years to 70 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  493. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  494. Recruiting
    Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06536868

    Age 18 years to 80 years (registered criteria)

    Led by Second Hospital of Shanxi Medical University; 1 listed hospital as study siteTaiyuan

  495. Recruiting
    Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06542159

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  496. Recruiting
    Primary Tumor Resection for M1a Stage Lung Cancer
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06547710

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  497. Recruiting
    Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06548711

    Age 18 years to 80 years (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

  498. Recruiting
    Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06554613

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  499. Recruiting
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06561386

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang

  500. Recruiting
    Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
    Phase
    Phase 4
    Started
    2024-05
    Posted
    Registry
    NCT06561620

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  501. Recruiting
    Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06562920

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  502. Recruiting
    Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06563999

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  503. Recruiting
    A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06564324

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  504. Recruiting
    Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06567015

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin

  505. Recruiting
    Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
    Phase
    N/A
    Started
    2024-09
    Posted
    Registry
    NCT06572540

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Shanghai, Zhengzhou

  506. Recruiting
    Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06574347

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  507. Recruiting
    A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06581419

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  508. Recruiting
    Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06582940

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  509. Recruiting
    Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06596915

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  510. Recruiting
    Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06598306

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  511. Recruiting
    Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06598527

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  512. Recruiting
    Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06607796

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  513. Recruiting
    Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06610734

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  514. Recruiting
    A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06612840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  515. Recruiting
    Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06613009

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Fuzhou, Hangzhou, Hefei, Jinan, Nanchang, Zhengzhou

  516. Recruiting
    A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06617416

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  517. Recruiting
    Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06621563

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  518. Recruiting
    The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06623487

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  519. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  520. Recruiting
    AI-Assisted Non-Contrast CT for Multi-Cancer Screening
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06632886

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  521. Recruiting
    Segmentectomy for Solid-dominant Lung Cancer
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06634966

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  522. Recruiting
    Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
    Phase
    N/A
    Started
    2024-05
    Posted
    Registry
    NCT06634979

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  523. Recruiting
    A Phase I Study of CFT8919 in Patients With Advanced NSCLC
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06641609

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  524. Recruiting
    Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
    Phase
    N/A
    Started
    2024-05
    Posted
    Registry
    NCT06644066

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  525. Recruiting
    Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT06644430

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  526. Recruiting
    Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06648317

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  527. Recruiting
    High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06652048

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  528. Recruiting
    Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06659042

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  529. Recruiting
    Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06663306

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  530. Recruiting
    A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06667908

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  531. Recruiting
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06668103

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangchun, Harbin, Shanghai, Wuhan

  532. Recruiting
    Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06674343

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  533. Recruiting
    Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06684418

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  534. Recruiting
    The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06692972

    Age 18 years to Not stated (registered criteria)

    Led by China-Japan Friendship Hospital; 1 listed hospital as study siteBeijing, Wuhan

  535. Recruiting
    Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06698965

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  536. Recruiting
    Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06699979

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  537. Recruiting
    Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06702826

    Age 18 years to 75 years (registered criteria)

    Led by Xiangya HospitalChangsha

  538. Recruiting
    Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06714708

    Age 18 years to Not stated (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  539. Recruiting
    Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06718309

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  540. Recruiting
    A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT06718972

    Age not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  541. Recruiting
    Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06719700

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  542. Recruiting
    Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06728852

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  543. Recruiting
    Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06730295

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  544. Recruiting
    Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06734182

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  545. Recruiting
    Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06734702

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  546. Recruiting
    Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06739031

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  547. Recruiting
    Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT06742021

    Age 18 years to 75 years (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  548. Recruiting
    Lymph Node Pathologic Grading Strategy
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06745830

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  549. Recruiting
    Liposomal Irinotecan and Apatinib in ES-SCLC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06749691

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  550. Recruiting
    Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06749860

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  551. Recruiting
    An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06749886

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  552. Recruiting
    Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06755684

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  553. Recruiting
    68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06756217

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  554. Recruiting
    A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06768151

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  555. Recruiting
    A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06775275

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  556. Recruiting
    Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06775678

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  557. Recruiting
    A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06780826

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  558. Recruiting
    Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
    Phase
    Phase 1
    Started
    2024-06
    Posted
    Registry
    NCT06813365

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  559. Recruiting
    Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT06843629

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  560. Recruiting
    Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06843707

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  561. Recruiting
    Trop2-targeted immunoPET Imaging of Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2024-12
    Posted
    Registry
    NCT06851663

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  562. Recruiting
    Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06863506

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  563. Recruiting
    A Study of JMT203 in Patients With Cancer Cachexia
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06868849

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  564. Recruiting
    A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06873555

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBengbu, Changsha

  565. Recruiting
    Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06911606

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  566. Recruiting
    Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06926179

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 2 listed hospitals as study sitesBeijing, Kunming

  567. Recruiting
    Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06956001

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan

  568. Recruiting
    A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
    Phase
    Phase 3
    Started
    2024-09
    Posted
    Registry
    NCT06970639

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  569. Recruiting
    The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06975384

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  570. Recruiting
    The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
    Phase
    N/A
    Started
    2024-07
    Posted
    Registry
    NCT06988579

    Age 40 years to 74 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  571. Recruiting
    Early Intervention Strategies for Lung Cancer
    Phase
    N/A
    Started
    2024-06
    Posted
    Registry
    NCT06988943

    Age 40 years to 74 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  572. Recruiting
    D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT07016126

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  573. Recruiting
    Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT07026110

    Age 18 years to 80 years (registered criteria)

    Led by Renji HospitalShanghai

  574. Recruiting
    Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer:A Prospective, Single-Arm, Phase II Study
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT07085182

    Age 18 years to 75 years (registered criteria)

    Led by Zibo Municipal HospitalZibo

  575. Recruiting
    Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
    Phase
    Not given
    Started
    2024-06
    Posted
    Registry
    NCT07131670

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  576. Recruiting
    Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT07239063

    Age not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  577. Recruiting
    Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT07399210

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  578. Recruiting
    Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT07433283

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou

  579. Recruiting
    Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT07439991

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  580. Recruiting
    An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT07444281

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  581. Recruiting
    A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT07463300

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 7 listed hospitals as study sitesChengdu, Hangzhou, Shenyang, Wuhan, Yangzhou

  582. Recruiting
    Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT07632664

    Age 65 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  583. Recruiting
    Shared Decision Making in Patients With Lung Cancer
    Phase
    Not given
    Started
    2023-02
    Posted
    Registry
    NCT05191485

    Age 18 years to Not stated (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  584. Recruiting
    Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
    Phase
    Phase 2/Phase 3
    Started
    2023-07
    Posted
    Registry
    NCT05623267

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  585. Recruiting
    Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
    Phase
    Phase 3
    Started
    2023-02
    Posted
    Registry
    NCT05717803

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  586. Recruiting
    Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
    Phase
    N/A
    Started
    2023-08
    Posted
    Registry
    NCT05754203

    Age 18 years to 75 years (registered criteria)

    Led by Xinqiao Hospital, Army Medical UniversityChongqing

  587. Recruiting
    Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05765877

    Age 18 years to Not stated (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  588. Recruiting
    Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05766800

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  589. Recruiting
    Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
    Phase
    Phase 1/Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05777278

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  590. Recruiting
    Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT05786924

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Jinan, Shanghai, Suzhou

  591. Recruiting
    A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05789082

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Harbin, Shanghai

  592. Recruiting
    Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-01
    Posted
    Registry
    NCT05800223

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  593. Recruiting
    Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
    Phase
    Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT05800340

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  594. Recruiting
    Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
    Phase
    Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT05825443

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  595. Recruiting
    Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT05830812

    Age 20 years to 80 years (registered criteria)

    Led by Union HospitalWuhan

  596. Recruiting
    Integrin αvβ6-targeted PET in Malignant Tumors
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT05835570

    Age 18 years to 85 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  597. Recruiting
    Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
    Phase
    Not given
    Started
    2023-05
    Posted
    Registry
    NCT05857800

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  598. Recruiting
    DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT05882058

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Hangzhou, Jinan, Nanchang, Shanghai

  599. Recruiting
    LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05886439

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  600. Recruiting
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05913089

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang

  601. Recruiting
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05920356

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou

  602. Recruiting
    A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT05924841

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  603. Recruiting
    A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05940532

    Age 18 years to 75 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  604. Recruiting
    Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-10
    Posted
    Registry
    NCT05965024

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  605. Recruiting
    Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT05965557

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  606. Recruiting
    Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT05978284

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  607. Recruiting
    Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05987826

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  608. Recruiting
    A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05989542

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  609. Recruiting
    Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT05990946

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  610. Recruiting
    Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
    Phase
    Not given
    Started
    2023-08
    Posted
    Registry
    NCT05997719

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  611. Recruiting
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06010329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  612. Recruiting
    Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06023212

    Age 10 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  613. Recruiting
    Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT06031181

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  614. Recruiting
    Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT06041776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  615. Recruiting
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-08
    Posted
    Registry
    NCT06043466

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  616. Recruiting
    Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT06043973

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Shandong First Medical UniversityJinan

  617. Recruiting
    Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer
    Phase
    N/A
    Started
    2023-10
    Posted
    Registry
    NCT06052098

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  618. Recruiting
    Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
    Phase
    N/A
    Started
    2023-05
    Posted
    Registry
    NCT06056115

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  619. Recruiting
    SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT06080776

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  620. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  621. Recruiting
    The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06109558

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  622. Recruiting
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06119581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang

  623. Recruiting
    Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06123754

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  624. Recruiting
    Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06125041

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Shandong First Medical UniversityJinan

  625. Recruiting
    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06131840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  626. Recruiting
    Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT06141226

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  627. Recruiting
    RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
    Phase
    Not given
    Started
    2023-11
    Posted
    Registry
    NCT06142058

    Age 18 years to Not stated (registered criteria)

    Led by Dapping HospitalChongqing

  628. Recruiting
    A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06147570

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  629. Recruiting
    COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT06168032

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  630. Recruiting
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170788

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou

  631. Recruiting
    To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06192849

    Age 18 years to Not stated (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  632. Recruiting
    Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06199895

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  633. Recruiting
    Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06205927

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  634. Recruiting
    Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06216782

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  635. Recruiting
    Effects of Digital Therapeutic in Whole Process Management of Lung Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT06230445

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  636. Recruiting
    DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
    Phase
    Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT06276283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  637. Recruiting
    Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06286150

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  638. Recruiting
    Assessment System of Sarcopenia in Lung Cancer Patients
    Phase
    Not given
    Started
    2023-11
    Posted
    Registry
    NCT06327594

    Age 40 years to 100 years (registered criteria)

    Led by West China HospitalChengdu

  639. Recruiting
    Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
    Phase
    Phase 1/Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT06343064

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  640. Recruiting
    Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06358222

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  641. Recruiting
    Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT06371482

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  642. Recruiting
    Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
    Phase
    Not given
    Started
    2023-10
    Posted
    Registry
    NCT06399926

    Age 18 years to Not stated (registered criteria)

    Led by Xiangya HospitalChangsha

  643. Recruiting
    Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
    Phase
    Not given
    Started
    2023-08
    Posted
    Registry
    NCT06413212

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  644. Recruiting
    a Single-arm, Single-center, Open Clinical Study
    Phase
    Not given
    Started
    2023-07
    Posted
    Registry
    NCT06431100

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  645. Recruiting
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-04
    Posted
    Registry
    NCT06508307

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  646. Recruiting
    A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT06512207

    Age 60 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  647. Recruiting
    Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
    Phase
    Not given
    Started
    2023-08
    Posted
    Registry
    NCT06534489

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  648. Recruiting
    Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
    Phase
    Not given
    Started
    2023-10
    Posted
    Registry
    NCT06730503

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  649. Recruiting
    Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
    Phase
    Not given
    Started
    2023-02
    Posted
    Registry
    NCT06790797

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  650. Recruiting
    Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT07041320

    Age 65 years to Not stated (registered criteria)

    Led by Anhui Chest HospitalHefei

  651. Recruiting
    Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT07070011

    Age 45 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  652. Recruiting
    Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT07328945

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  653. Recruiting
    ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
    Phase
    N/A
    Started
    2022-02
    Posted
    Registry
    NCT03786003

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  654. Recruiting
    SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
    Phase
    N/A
    Started
    2022-02
    Posted
    Registry
    NCT04527419

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  655. Recruiting
    Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
    Phase
    N/A
    Started
    2022-05
    Posted
    Registry
    NCT04631770

    Age not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  656. Recruiting
    Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT04728724

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  657. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  658. Recruiting
    Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
    Phase
    N/A
    Started
    2022-10
    Posted
    Registry
    NCT04973293

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  659. Recruiting
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05168566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou

  660. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Posted
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  661. Recruiting
    Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05241028

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  662. Recruiting
    First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05271916

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  663. Recruiting
    Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
    Phase
    Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05284539

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  664. Recruiting
    MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
    Phase
    Phase 2
    Started
    2022-06
    Posted
    Registry
    NCT05286957

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  665. Recruiting
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05288205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou

  666. Recruiting
    Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
    Phase
    Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05334277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Foshan, Guangzhou, Hangzhou, Jiangmen, Nanchang, Shenyang, Urumqi, Wuhan, Xi'an, Xuzhou, Zhengzhou

  667. Recruiting
    Patient's Whole Process Follow-up Management(HOPE-1)
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05339568

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Shandong First Medical UniversityJinan

  668. Recruiting
    EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
    Phase
    Early phase 1
    Started
    2022-05
    Posted
    Registry
    NCT05341492

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  669. Recruiting
    SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
    Phase
    Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05351788

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  670. Recruiting
    Multiomics Tumor Evolution Model of NSCLC
    Phase
    Not given
    Started
    2022-04
    Posted
    Registry
    NCT05352035

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  671. Recruiting
    AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-07
    Posted
    Registry
    NCT05377658

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  672. Recruiting
    Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05378334

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  673. Recruiting
    Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
    Phase
    Phase 3
    Started
    2022-06
    Posted
    Registry
    NCT05382728

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai

  674. Recruiting
    Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
    Phase
    Not given
    Started
    2022-08
    Posted
    Registry
    NCT05457049

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFoshan, Guangzhou, Shantou, Zhongshan

  675. Recruiting
    A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05482568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai

  676. Recruiting
    An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
    Phase
    Not given
    Started
    2022-08
    Posted
    Registry
    NCT05486650

    Age 18 years to 75 years (registered criteria)

    Led by Xinqiao Hospital, Army Medical UniversityChongqing

  677. Recruiting
    A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
    Phase
    Phase 3
    Started
    2022-12
    Posted
    Registry
    NCT05487391

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  678. Recruiting
    JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05490472

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan

  679. Recruiting
    China Lung Cancer Screening (CLUS) Study Version 3.0
    Phase
    N/A
    Started
    2022-01
    Posted
    Registry
    NCT05494021

    Age 45 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  680. Recruiting
    A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05498064

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  681. Recruiting
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05498428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai

  682. Recruiting
    Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
    Phase
    Phase 2
    Started
    2022-02
    Posted
    Registry
    NCT05503667

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  683. Recruiting
    Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05536505

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan

  684. Recruiting
    A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05543330

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  685. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  686. Recruiting
    Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05584267

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  687. Recruiting
    Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
    Phase
    Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05686434

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  688. Recruiting
    Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
    Phase
    Phase 1
    Started
    2022-05
    Posted
    Registry
    NCT06128148

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  689. Recruiting
    Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT06241807

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  690. Recruiting
    Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
    Phase
    N/A
    Started
    2022-01
    Posted
    Registry
    NCT06404164

    Age not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  691. Recruiting
    Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT06706713

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou

  692. Recruiting
    Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06775821

    Age 20 years to 90 years (registered criteria)

    Led by First Affiliated Hospital of Kunming Medical University; 1 listed hospital as study siteKunming

  693. Recruiting
    A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT07231068

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Zhengzhou

  694. Recruiting
    Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies.
    Phase
    Not given
    Started
    2022-12
    Posted
    Registry
    NCT07370077

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  695. Recruiting
    Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT07632365

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  696. Recruiting
    Cardiorespiratory Fitness After Lobectomy Versus Sublobar Resection
    Phase
    Not given
    Started
    2022-08
    Posted
    Registry
    NCT07841249

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  697. Recruiting
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
    Phase
    Phase 2
    Started
    2021-08
    Posted
    Registry
    NCT04777084

    Age 18 years to 75 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  698. Recruiting
    Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
    Phase
    Phase 3
    Started
    2021-04
    Posted
    Registry
    NCT04829708

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  699. Recruiting
    Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2021-01
    Posted
    Registry
    NCT04842812

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  700. Recruiting
    To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
    Phase
    Phase 3
    Started
    2021-06
    Posted
    Registry
    NCT04853342

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  701. Recruiting
    Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
    Phase
    Phase 1
    Started
    2021-07
    Posted
    Registry
    NCT04886804

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou

  702. Recruiting
    A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
    Phase
    Phase 2
    Started
    2021-01
    Posted
    Registry
    NCT04905056

    Age 18 years to 85 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  703. Recruiting
    A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
    Phase
    Phase 1
    Started
    2021-08
    Posted
    Registry
    NCT04913285

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHarbin, Linyi, Shanghai

  704. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  705. Recruiting
    Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field
    Phase
    N/A
    Started
    2021-07
    Posted
    Registry
    NCT04944563

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  706. Recruiting
    A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2021-03
    Posted
    Registry
    NCT04951635

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  707. Recruiting
    Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2021-03
    Posted
    Registry
    NCT04952272

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  708. Recruiting
    MRD Monitoring in Lung Cancer After Resection
    Phase
    Not given
    Started
    2021-09
    Posted
    Registry
    NCT04976296

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  709. Recruiting
    Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
    Phase
    Phase 3
    Started
    2021-06
    Posted
    Registry
    NCT04980716

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  710. Recruiting
    A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-12
    Posted
    Registry
    NCT04996121

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  711. Recruiting
    Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
    Phase
    Phase 2
    Started
    2021-08
    Posted
    Registry
    NCT05011487

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  712. Recruiting
    ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05014464

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  713. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai

  714. Recruiting
    Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
    Phase
    Phase 2
    Started
    2021-03
    Posted
    Registry
    NCT05053802

    Age 18 years to 79 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesShanghai

  715. Recruiting
    Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
    Phase
    Phase 3
    Started
    2021-10
    Posted
    Registry
    NCT05055908

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  716. Recruiting
    Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
    Phase
    Not given
    Started
    2021-10
    Posted
    Registry
    NCT05059951

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  717. Recruiting
    First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 1/Phase 2
    Started
    2021-10
    Posted
    Registry
    NCT05099172

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Taizhou

  718. Recruiting
    A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2021-10
    Posted
    Registry
    NCT05104788

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  719. Recruiting
    Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer
    Phase
    N/A
    Started
    2021-04
    Posted
    Registry
    NCT05150145

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang

  720. Recruiting
    Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05187338

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  721. Recruiting
    Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
    Phase
    N/A
    Started
    2021-01
    Posted
    Registry
    NCT05552846

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  722. Recruiting
    Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)
    Phase
    N/A
    Started
    2021-11
    Posted
    Registry
    NCT05559645

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  723. Recruiting
    Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
    Phase
    Not given
    Started
    2021-09
    Posted
    Registry
    NCT05598528

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  724. Recruiting
    Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2021-12
    Posted
    Registry
    NCT05751018

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  725. Recruiting
    Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
    Phase
    Not given
    Started
    2021-01
    Posted
    Registry
    NCT06369181

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  726. Recruiting
    Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
    Phase
    Phase 2
    Started
    2021-05
    Posted
    Registry
    NCT07198217

    Age 18 years to 75 years (registered criteria)

    Led by Zibo Municipal HospitalZibo

  727. Recruiting
    Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
    Phase
    N/A
    Started
    2020-04
    Posted
    Registry
    NCT04209218

    Age 50 years to 90 years (registered criteria)

    Led by Peking University First HospitalBeijing

  728. Recruiting
    A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
    Phase
    Phase 3
    Started
    2020-07
    Posted
    Registry
    NCT04316364

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Zhengzhou

  729. Recruiting
    Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2020-03
    Posted
    Registry
    NCT04322617

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  730. Recruiting
    Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
    Phase
    Phase 2
    Started
    2020-04
    Posted
    Registry
    NCT04322890

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  731. Recruiting
    Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
    Phase
    Not given
    Started
    2020-03
    Posted
    Registry
    NCT04324164

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  732. Recruiting
    PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
    Phase
    Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04539977

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  733. Recruiting
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
    Phase
    Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04557449

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou

  734. Recruiting
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2020-11
    Posted
    Registry
    NCT04606446

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an

  735. Recruiting
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    Phase
    Phase 2/Phase 3
    Started
    2020-12
    Posted
    Registry
    NCT04613596

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  736. Recruiting
    The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
    Phase
    Not given
    Started
    2020-06
    Posted
    Registry
    NCT05477979

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  737. Recruiting
    Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
    Phase
    Phase 2
    Started
    2019-03
    Posted
    Registry
    NCT03872661

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  738. Recruiting
    APG-2449 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2019-05
    Posted
    Registry
    NCT03917043

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Wuhan

  739. Recruiting
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Posted
    Registry
    NCT04270591

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  740. Recruiting
    The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
    Phase
    Not given
    Started
    2019-05
    Posted
    Registry
    NCT04286841

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  741. Recruiting
    Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery
    Phase
    N/A
    Started
    2019-10
    Posted
    Registry
    NCT04451473

    Age 18 years to 85 years (registered criteria)

    Led by Second Hospital of Shandong UniversityJinan

  742. Recruiting
    Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
    Phase
    N/A
    Started
    2019-10
    Posted
    Registry
    NCT04937283

    Age 20 years to 79 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 8 listed hospitals as study sitesHangzhou, Hefei, Nantong, Ningbo, Shanghai, Xuzhou

  743. Recruiting
    Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
    Phase
    Early phase 1
    Started
    2019-09
    Posted
    Registry
    NCT05060796

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  744. Recruiting
    Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT05701787

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  745. Recruiting
    Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
    Phase
    Not given
    Started
    2019-08
    Posted
    Registry
    NCT05838053

    Age 20 years to 79 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  746. Recruiting
    Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
    Phase
    Not given
    Started
    2019-11
    Posted
    Registry
    NCT06255197

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  747. Recruiting
    LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
    Phase
    Not given
    Started
    2019-06
    Posted
    Registry
    NCT06778512

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  748. Recruiting
    Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06950697

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Chao-Yang Hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou

  749. Recruiting
    The Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression
    Phase
    Not given
    Started
    2019-02
    Posted
    Registry
    NCT07779005

    Age 18 years to 75 years (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  750. Recruiting
    A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
    Phase
    Phase 1
    Started
    2018-04
    Posted
    Registry
    NCT03460977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou

  751. Recruiting
    Survival Outcomes of Lung Cancer
    Phase
    Not given
    Started
    2018-08
    Posted
    Registry
    NCT03647098

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  752. Recruiting
    Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2018-11
    Posted
    Registry
    NCT03755739

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  753. Recruiting
    Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
    Phase
    N/A
    Started
    2018-11
    Posted
    Registry
    NCT03769129

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  754. Recruiting
    TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2018-12
    Posted
    Registry
    NCT03778814

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  755. Recruiting
    Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
    Phase
    Not given
    Started
    2018-01
    Posted
    Registry
    NCT05636605

    Age 18 years to 80 years (registered criteria)

    Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou

  756. Recruiting
    iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
    Phase
    Not given
    Started
    2017-07
    Posted
    Registry
    NCT03192501

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  757. Recruiting
    Study of High Efficient Killing Cell Therapy for Advanced NSCLC
    Phase
    Phase 1
    Started
    2017-09
    Posted
    Registry
    NCT03193567

    Age 18 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  758. Recruiting
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
    Phase
    Phase 1
    Started
    2017-07
    Posted
    Registry
    NCT03198052

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou

  759. Recruiting
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
    Phase
    Phase 1
    Started
    2017-07
    Posted
    Registry
    NCT03198546

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou

  760. Recruiting
    Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
    Phase
    Phase 2
    Started
    2017-09
    Posted
    Registry
    NCT03351842

    Age 19 years to 70 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  761. Recruiting
    Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
    Phase
    Phase 2
    Started
    2017-08
    Posted
    Registry
    NCT03392233

    Age 18 years to 85 years (registered criteria)

    Led by Renji HospitalShanghai

  762. Recruiting
    Integrative Analysis of Large-cell Lung Cancer
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT02917369

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai

  763. Recruiting
    Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2016-07
    Posted
    Registry
    NCT04977791

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  764. Recruiting
    Molecular Analysis and Treatment Options of SCLC
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT05945745

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  765. Recruiting
    Association of Psychological Distress in Patients With Lung Cancer
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT06218901

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  766. Recruiting
    Non-risk Based Lang Cancer Screening With a One-off LDCT
    Phase
    N/A
    Started
    2015-12
    Posted
    Registry
    NCT04938804

    Age 40 years to 74 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  767. Recruiting
    A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
    Phase
    Not given
    Started
    2012-09
    Posted
    Registry
    NCT01994057

    Age 18 years to 85 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  768. Recruiting
    A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2008-01
    Posted
    Registry
    NCT02889666

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  769. Not yet recruiting
    A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
    Phase
    Phase 1/Phase 2
    Started
    2027-12
    Posted
    Registry
    NCT05745740

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  770. Not yet recruiting
    Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer
    Phase
    N/A
    Started
    2027-01
    Posted
    Registry
    NCT07928882

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  771. Not yet recruiting
    Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung Cancer.
    Phase
    Phase 2
    Started
    2027-01
    Posted
    Registry
    NCT07944313

    Age 60 years to 90 years (registered criteria)

    Led by Quanzhou First Hospital, Fujian Medical UniversityQuanzhou

  772. Not yet recruiting
    Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT06706219

    Age 18 years to 70 years (registered criteria)

    Led by Hunan Cancer Hospital; 1 listed hospital as study siteChangsha

  773. Not yet recruiting
    SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT06772363

    Age 18 years to Not stated (registered criteria)

    Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou

  774. Not yet recruiting
    SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT06775015

    Age 18 years to Not stated (registered criteria)

    Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou

  775. Not yet recruiting
    SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT06775587

    Age 18 years to Not stated (registered criteria)

    Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou

  776. Not yet recruiting
    Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07001995

    Age 18 years to 80 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  777. Not yet recruiting
    A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07014878

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  778. Not yet recruiting
    Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07258147

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  779. Not yet recruiting
    Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07303881

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  780. Not yet recruiting
    A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07307443

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  781. Not yet recruiting
    NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07318636

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  782. Not yet recruiting
    A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07318883

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  783. Not yet recruiting
    A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07338396

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Guangzhou

  784. Not yet recruiting
    Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07343479

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  785. Not yet recruiting
    Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07347977

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Ningbo UniversityNingbo

  786. Not yet recruiting
    Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07352176

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  787. Not yet recruiting
    Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07357532

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  788. Not yet recruiting
    Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
    Phase
    Phase 4
    Started
    2026-01
    Posted
    Registry
    NCT07358520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xuzhou

  789. Not yet recruiting
    Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07358689

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  790. Not yet recruiting
    Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07360132

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  791. Not yet recruiting
    Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07365410

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  792. Not yet recruiting
    18F-FAPI PET in Lung Cancer
    Phase
    Not given
    Started
    2026-02
    Posted
    Registry
    NCT07370805

    Age 20 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  793. Not yet recruiting
    A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
    Phase
    Not given
    Started
    2026-02
    Posted
    Registry
    NCT07375979

    Age 40 years to 74 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesChangchun, Kunming, Shanghai, Shenyang, Zhengzhou

  794. Not yet recruiting
    Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07379398

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  795. Not yet recruiting
    Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07381543

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  796. Not yet recruiting
    Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07383116

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  797. Not yet recruiting
    Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07395375

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  798. Not yet recruiting
    Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07398560

    Age 18 years to 99 years (registered criteria)

    Led by Third Affiliated Hospital of Harbin Medical UniversityHarbin

  799. Not yet recruiting
    IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07402070

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  800. Not yet recruiting
    Tubeless Strategy for Enhanced Recovery After Sublobar Resection
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07409129

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  801. Not yet recruiting
    ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07410611

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  802. Not yet recruiting
    Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07413952

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  803. Not yet recruiting
    A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07414927

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  804. Not yet recruiting
    Video Double-Lumen Tube for Secondary Pulmonary Resection
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07467005

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHangzhou

  805. Not yet recruiting
    A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
    Phase
    Phase 4
    Started
    2026-04
    Posted
    Registry
    NCT07469488

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  806. Not yet recruiting
    A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
    Phase
    Phase 4
    Started
    2026-05
    Posted
    Registry
    NCT07485920

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 1 listed hospital as study siteQingdao, Yantai

  807. Not yet recruiting
    Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07486648

    Age 18 years to Not stated (registered criteria)

    Led by Shanxi Cancer Hospital; 1 listed hospital as study siteBeijing, Taiyuan

  808. Not yet recruiting
    Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07493980

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  809. Not yet recruiting
    Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07501169

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  810. Not yet recruiting
    Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07517640

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  811. Not yet recruiting
    Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07538193

    Age 18 years to Not stated (registered criteria)

    Led by Tangdu HospitalXi'an

  812. Not yet recruiting
    A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07538973

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesQingdao, Shanghai

  813. Not yet recruiting
    Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07545213

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou

  814. Not yet recruiting
    A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07550842

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangzhou, Harbin, Shanghai, Shenyang, Taizhou, Wuhan, Zhengzhou

  815. Not yet recruiting
    Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07551414

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  816. Not yet recruiting
    GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07554859

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  817. Not yet recruiting
    Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07558200

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  818. Not yet recruiting
    Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07560358

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  819. Not yet recruiting
    Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07561983

    Age 18 years to 80 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  820. Not yet recruiting
    A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07583316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  821. Not yet recruiting
    A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07583771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  822. Not yet recruiting
    5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07589101

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  823. Not yet recruiting
    Preoperative Decision-Making in Patients With Pulmonary Nodules Suspected of Lung Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07590596

    Age 18 years to Not stated (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  824. Not yet recruiting
    Application of Electromagnetic Navigation System in Pulmonary Nodule Localization
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07595120

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  825. Not yet recruiting
    Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07596524

    Age 1 year to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan

  826. Not yet recruiting
    A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07601048

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  827. Not yet recruiting
    A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(Phase II Study Ongoing)
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07609251

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  828. Not yet recruiting
    Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07617389

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  829. Not yet recruiting
    Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07618793

    Age 18 years to 75 years (registered criteria)

    Led by Xuanwu HospitalBeijing

  830. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  831. Not yet recruiting
    Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07624214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  832. Not yet recruiting
    Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07627321

    Age 18 years to 75 years (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  833. Not yet recruiting
    Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07647692

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  834. Not yet recruiting
    A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07661173

    Age 18 years to Not stated (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  835. Not yet recruiting
    A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07663630

    Age 18 years to Not stated (registered criteria)

    Led by The University of Hong Kong–Shenzhen HospitalShenzhen

  836. Not yet recruiting
    Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07670715

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  837. Not yet recruiting
    A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer
    Phase
    Early phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07673419

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  838. Not yet recruiting
    Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
    Phase
    Phase 4
    Started
    2026-07
    Posted
    Registry
    NCT07674368

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  839. Not yet recruiting
    Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07674524

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  840. Not yet recruiting
    A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07686185

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  841. Not yet recruiting
    Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07698990

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  842. Not yet recruiting
    HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07699757

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  843. Not yet recruiting
    The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07704645

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  844. Not yet recruiting
    A Phase 2 Study of ABSK043 Combined With Osimertinib
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07710612

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan

  845. Not yet recruiting
    JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
    Phase
    N/A
    Started
    2026-07
    Posted
    Registry
    NCT07714304

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai

  846. Not yet recruiting
    Rehabilitation With Wearable Monitors for Post-Lung Cancer Surgery
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07733492

    Age 18 years to 85 years (registered criteria)

    Led by West China HospitalChengdu

  847. Not yet recruiting
    Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer Patients
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07742800

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  848. Not yet recruiting
    Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07745790

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  849. Not yet recruiting
    Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07752589

    Age 18 years to 80 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  850. Not yet recruiting
    A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07771764

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  851. Not yet recruiting
    Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07775040

    Age 18 years to 75 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  852. Not yet recruiting
    Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07778940

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  853. Not yet recruiting
    The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07780578

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  854. Not yet recruiting
    Digital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07797075

    Age 18 years to 85 years (registered criteria)

    Led by West China HospitalChengdu

  855. Not yet recruiting
    Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07807722

    Age 18 years to 70 years (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  856. Not yet recruiting
    Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors
    Phase
    Phase 1
    Started
    2026-09
    Posted
    Registry
    NCT07815951

    Age 18 years to 75 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  857. Not yet recruiting
    Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07819591

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  858. Not yet recruiting
    Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07819669

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shenzhen

  859. Not yet recruiting
    A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07827261

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  860. Not yet recruiting
    AI-Assisted Chest CT Interpretation Across the Lung Cancer Care Continuum
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07829640

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  861. Not yet recruiting
    5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies
    Phase
    N/A
    Started
    2026-11
    Posted
    Registry
    NCT07830095

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  862. Not yet recruiting
    A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07831863

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  863. Not yet recruiting
    A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07833202

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanchang

  864. Not yet recruiting
    Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07842471

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  865. Not yet recruiting
    Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07842887

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  866. Not yet recruiting
    Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07845916

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  867. Not yet recruiting
    Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07849400

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Jiaxing

  868. Not yet recruiting
    An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07849712

    Age 75 days to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  869. Not yet recruiting
    A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-11
    Posted
    Registry
    NCT07865910

    Age 18 days to 75 days (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesAnyang, Beijing, Chongqing, Guangzhou, Jinan, Nanning, Qingdao, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou, Zunyi

  870. Not yet recruiting
    MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
    Phase
    N/A
    Started
    2026-11
    Posted
    Registry
    NCT07873086

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  871. Not yet recruiting
    Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07874282

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  872. Not yet recruiting
    Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07874464

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  873. Not yet recruiting
    Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07875465

    Age 18 years to Not stated (registered criteria)

    Led by Hangzhou Cancer HospitalHangzhou

  874. Not yet recruiting
    Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07875920

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  875. Not yet recruiting
    Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07878871

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  876. Not yet recruiting
    Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07882628

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chao-Yang Hospital; 4 listed hospitals as study sitesBeijing, Changsha

  877. Not yet recruiting
    Union-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07882758

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  878. Not yet recruiting
    MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07885709

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  879. Not yet recruiting
    Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07889297

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  880. Not yet recruiting
    Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07890636

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  881. Not yet recruiting
    SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
    Phase
    Phase 3
    Started
    2026-11
    Posted
    Registry
    NCT07895992

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  882. Not yet recruiting
    A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-12
    Posted
    Registry
    NCT07896005

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai

  883. Not yet recruiting
    ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07897188

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  884. Not yet recruiting
    Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07909863

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  885. Not yet recruiting
    Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-11
    Posted
    Registry
    NCT07912268

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Fuzhou, Harbin, Nanchang, Shanghai

  886. Not yet recruiting
    Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07936578

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Cancer Hospital of Guizhou Medical UniversityGuiyang

  887. Not yet recruiting
    Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06688656

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  888. Not yet recruiting
    MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
    Phase
    Early phase 1
    Started
    2025-01
    Posted
    Registry
    NCT06735508

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  889. Not yet recruiting
    The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06739421

    Age 18 years to 90 years (registered criteria)

    Led by China-Japan Friendship HospitalBeijing

  890. Not yet recruiting
    The Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06768853

    Age 18 years to 70 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  891. Not yet recruiting
    Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06780839

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  892. Not yet recruiting
    Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06784206

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  893. Not yet recruiting
    Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study
    Phase
    Phase 4
    Started
    2025-02
    Posted
    Registry
    NCT06785584

    Age 18 years to Not stated (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  894. Not yet recruiting
    Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06786208

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  895. Not yet recruiting
    A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06786312

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer Hospital; 3 listed hospitals as study sitesFuzhou, Xiamen

  896. Not yet recruiting
    The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06789276

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  897. Not yet recruiting
    Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06793228

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer Hospital; 1 listed hospital as study siteLuoyang, Zhengzhou

  898. Not yet recruiting
    Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06820762

    Age 18 years to 75 years (registered criteria)

    Led by Second Hospital of Dalian Medical University; 1 listed hospital as study siteDalian, Shenyang

  899. Not yet recruiting
    Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06828757

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  900. Not yet recruiting
    Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06837948

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  901. Not yet recruiting
    Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06848426

    Age 18 years to 75 years (registered criteria)

    Led by Jiangxi Provincial People's HospitalNanchang

  902. Not yet recruiting
    Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06851819

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  903. Not yet recruiting
    Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06885840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou

  904. Not yet recruiting
    Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
    Phase
    Phase 4
    Started
    2025-04
    Posted
    Registry
    NCT06931145

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  905. Not yet recruiting
    Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
    Phase
    Phase 4
    Started
    2025-04
    Posted
    Registry
    NCT06951841

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  906. Not yet recruiting
    Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06961188

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  907. Not yet recruiting
    Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
    Phase
    Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06961201

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  908. Not yet recruiting
    A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06963502

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou

  909. Not yet recruiting
    NAD+ Supplement(NMN)With Radioimmunotherapy in Advanced NSCLC
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06966583

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  910. Not yet recruiting
    A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06977828

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  911. Not yet recruiting
    Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT06994078

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  912. Not yet recruiting
    Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06998719

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  913. Not yet recruiting
    Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07004712

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  914. Not yet recruiting
    AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07005791

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  915. Not yet recruiting
    A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07031154

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  916. Not yet recruiting
    Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT07035444

    Age 18 years to Not stated (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  917. Not yet recruiting
    Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07035860

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  918. Not yet recruiting
    A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07036185

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  919. Not yet recruiting
    A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07038460

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Hangzhou

  920. Not yet recruiting
    Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07064876

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  921. Not yet recruiting
    A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07083375

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  922. Not yet recruiting
    A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07086326

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Xi'an

  923. Not yet recruiting
    Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07093762

    Age 18 years to Not stated (registered criteria)

    Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou

  924. Not yet recruiting
    Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07097948

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  925. Not yet recruiting
    A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07101627

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary Hospital; 1 listed hospital as study siteNanjing, Shanghai

  926. Not yet recruiting
    A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07103408

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  927. Not yet recruiting
    Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07129161

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Xi'an

  928. Not yet recruiting
    Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07135297

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 4 listed hospitals as study sitesBeijing, Nanjing, Ningbo, Shanghai, Zhengzhou

  929. Not yet recruiting
    Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07150416

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  930. Not yet recruiting
    Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07156604

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  931. Not yet recruiting
    AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07158840

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  932. Not yet recruiting
    Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07169903

    Age 20 years to 79 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  933. Not yet recruiting
    Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07172412

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  934. Not yet recruiting
    Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07179445

    Age 18 years to 100 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  935. Not yet recruiting
    High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07182708

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  936. Not yet recruiting
    Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07185308

    Age 18 years to Not stated (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  937. Not yet recruiting
    A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07198620

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  938. Not yet recruiting
    Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07199010

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  939. Not yet recruiting
    Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07200154

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  940. Not yet recruiting
    A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07200947

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  941. Not yet recruiting
    Penfluridol for Relapsed/Refractory Small Cell Cancers
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07206563

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  942. Not yet recruiting
    Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07242274

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  943. Not yet recruiting
    Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07244926

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  944. Not yet recruiting
    The Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07277088

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  945. Not yet recruiting
    Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07286942

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  946. Not yet recruiting
    Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07287904

    Age 18 years to 80 years (registered criteria)

    Led by Union HospitalWuhan

  947. Not yet recruiting
    Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06236997

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer Hospital; 1 listed hospital as study siteWuhan, Zhengzhou

  948. Not yet recruiting
    A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06254599

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  949. Not yet recruiting
    Myeloprotection With Trilaciclib in Pan-cancer Population
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06297811

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  950. Not yet recruiting
    Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06332950

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  951. Not yet recruiting
    Clinical Study of 18F-Alfatide Injection PET/CT
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06416852

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  952. Not yet recruiting
    A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
    Phase
    N/A
    Started
    2024-06
    Posted
    Registry
    NCT06422637

    Age 40 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  953. Not yet recruiting
    Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
    Phase
    N/A
    Started
    2024-06
    Posted
    Registry
    NCT06453889

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  954. Not yet recruiting
    Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06456138

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  955. Not yet recruiting
    Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06475755

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  956. Not yet recruiting
    A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06524518

    Age 18 years to 80 years (registered criteria)

    Led by Xuanwu HospitalBeijing

  957. Not yet recruiting
    Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer
    Phase
    N/A
    Started
    2024-09
    Posted
    Registry
    NCT06580665

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Wenzhou, Wuhan

  958. Not yet recruiting
    Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06585059

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  959. Not yet recruiting
    A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06585644

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  960. Not yet recruiting
    A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06594874

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  961. Not yet recruiting
    Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06604351

    Age 18 years to 80 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  962. Not yet recruiting
    TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
    Phase
    Early phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06619886

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  963. Not yet recruiting
    Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06620822

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  964. Not yet recruiting
    Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06634667

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  965. Not yet recruiting
    A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06690671

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  966. Not yet recruiting
    Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-12
    Posted
    Registry
    NCT06704620

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  967. Not yet recruiting
    Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT06709274

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Chengdu, Foshan, Guangzhou, Nanjing, Nantong, Shenzhen, Wuhan

  968. Not yet recruiting
    A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06724263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  969. Not yet recruiting
    Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06752408

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  970. Not yet recruiting
    The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-08
    Posted
    Registry
    NCT05496166

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  971. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  972. Not yet recruiting
    Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT05802654

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  973. Not yet recruiting
    ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
    Phase
    Not given
    Started
    2023-04
    Posted
    Registry
    NCT05822284

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya HospitalChangsha

  974. Not yet recruiting
    A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-07
    Posted
    Registry
    NCT05940116

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  975. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

  976. Not yet recruiting
    Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
    Phase
    Phase 1
    Started
    2023-09
    Posted
    Registry
    NCT06015568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBengbu, Changsha, Shanghai

  977. Not yet recruiting
    Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06102161

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  978. Not yet recruiting
    Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06109402

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  979. Not yet recruiting
    A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06142617

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  980. Not yet recruiting
    Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
    Phase
    Phase 2
    Started
    2022-01
    Posted
    Registry
    NCT05132985

    Age 18 years to 75 years (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  981. Not yet recruiting
    The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05411809

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  982. Not yet recruiting
    Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
    Phase
    Phase 2
    Started
    2021-08
    Posted
    Registry
    NCT04846634

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteNanchang, Tianjin

  983. Enrolling by invitation
    Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07373899

    Age not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  984. Enrolling by invitation
    Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07738367

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  985. Enrolling by invitation
    Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07920822

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  986. Enrolling by invitation
    Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06883136

    Age 60 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Shandong First Medical UniversityJinan

  987. Enrolling by invitation
    The Effect of Esketamine Combined With Dexmedetomidine on Postoperative Recovery Quality in Patients Undergoing Thoracoscopic Surgery
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT07125573

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Kunming Medical UniversityKunming

  988. Enrolling by invitation
    Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07373951

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  989. Enrolling by invitation
    Spontaneous Breathing Mode: A Risk for Hypoxemia During OLV?
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07494006

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  990. Enrolling by invitation
    Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07916129

    Age 18 years to 85 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  991. Enrolling by invitation
    the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06370416

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  992. Enrolling by invitation
    Perioperative Treatment Outcomes of Early NSCLC
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06610240

    Age not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  993. Enrolling by invitation
    Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06690216

    Age 18 years to Not stated (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  994. Enrolling by invitation
    INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
    Phase
    Early phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06747832

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWeifang

  995. Enrolling by invitation
    Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06773156

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  996. Enrolling by invitation
    LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT06876675

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  997. Enrolling by invitation
    Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06962449

    Age not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  998. Enrolling by invitation
    ⁶⁸Ga-DPA in the Lung Cancer Diagnosis
    Phase
    Early phase 1
    Started
    2024-09
    Posted
    Registry
    NCT07023068

    Age 18 years to 85 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  999. Enrolling by invitation
    The Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT07060625

    Age 18 years to 85 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  1000. Enrolling by invitation
    Application of Generative Artificial Intelligence in Perioperative Personalized Rehabilitation for Older Adults With Lung Cancer
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT07915193

    Age 65 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  1001. Enrolling by invitation
    Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study
    Phase
    N/A
    Started
    2023-01
    Posted
    Registry
    NCT06028412

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  1002. Enrolling by invitation
    Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06281964

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  1003. Enrolling by invitation
    Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06816966

    Age 18 years to Not stated (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1004. Enrolling by invitation
    Personalized SBRT in Early-Stage Peripheral NSCLC
    Phase
    Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT07167459

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1005. Enrolling by invitation
    Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT04762459

    Age 18 years to 130 years (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  1006. Enrolling by invitation
    The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
    Phase
    Not given
    Started
    2021-01
    Posted
    Registry
    NCT06647836

    Age 18 years to 80 years (registered criteria)

    Led by Union HospitalWuhan

  1007. Enrolling by invitation
    Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
    Phase
    Not given
    Started
    2021-01
    Posted
    Registry
    NCT06730477

    Age 18 years to 80 years (registered criteria)

    Led by Union HospitalWuhan

  1008. Enrolling by invitation
    FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT06759857

    Age 18 months to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Where these numbers come from

Papers

23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions